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Abstract
Background: CYP2E1 is a member of the cytochrome P450 superfamily, which is involved in the metabolism and activation
of both endobiotics and xenobiotics. The genetic polymorphisms of CYP2E1 gene (Chromosome 10q26.3, Accession
Number NC_000010.10) are reported to be related to the development of several mental diseases and to be involved in the
clinical efficacy of some psychiatric medications. We investigated the possible association of CYP2E1 polymorphisms with
susceptibility to schizophrenia in the Chinese Han Population as well as the relationship with response to risperidone in
schizophrenia patients.
Methods: In a case-control study, we identified 11 polymorphisms in the 5’ flanking region of CYP2E1 in 228 schizophrenia
patients and 384 healthy controls of Chinese Han origin. From among the cases, we chose 130 patients who had undergone
8 weeks of risperidone monotherapy to examine the relationship between their response to risperidone and CYP2E1
polymorphisms. Clinical efficacy was assessed using the Brief Psychiatric Rating Scale (BPRS).
Results: Statistically significant differences in allele or genotype frequencies were found between cases and controls at
rs8192766 (genotype p=0.0048, permutation p=0.0483) and rs2070673 (allele: p=0.0018, permutation p=0.0199,
OR=1.4528 95%CI=1.1487–1.8374; genotype: p=0.0020, permutation p=0.0225). In addition, a GTCAC haplotype
containing 5 SNPs (rs3813867, rs2031920, rs2031921, rs3813870 and rs2031922) was observed to be significantly associated
with schizophrenia (p=7.47E-12, permutation p,0.0001). However, no association was found between CYP2E1
polymorphisms/haplotypes and risperidone response.
Conclusions: Our results suggest that CYP2E1 may be a potential risk gene for schizophrenia in the Chinese Han population.
However, polymorphisms of the CYP2E1 gene may not contribute significantly to individual differences in the therapeutic
efficacy of risperidone. Further studies in larger groups are warranted to confirm our results.
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Introduction
Schizophrenia (OMIM: 181500) is a complex and severe mental
disorder with a prevalence of approximately 1% in the population
worldwide [1] and is characterized by psychotic manifestations,
such as hallucinations, delusions and cognitive deficits [2].
Although family, twin, and adoption studies provide strong
evidence that genetic factors play a crucial etiological role in the
disease, with heritability estimated at up to 80%, key components
and relevant pathways underlying the disease have still to be
identified. Recent genome-wide association studies (GWAS) have
provided new evidence for genetic predisposition by discovering
hundreds of thousands of single nucleotide polymorphisms (SNPs)
and copy number variations (CNVs) related to schizophrenia
covering the whole human genome [3,4,5]. Current GWAS
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e34809
Q)studies support the theory that particular loci are important in
certain populations [6].
Cytochrome P450 enzymes (P450s) constitute a superfamily of
hemeproteins which play a central role in the oxidative
metabolism and biotransformation of a variety of endogenous
and exogenous compounds [7]. Interindividual variability in the
expression of P450 genes contributes significantly to the difference
in the disposition of numerous substrates, including the metabo-
lites of steroids, environmental toxins and drugs [8]. CYP2E1, a
key member of the P450 superfamily, is involved in the
metabolism and bioactivation of a large number of low molecular
weight compounds, many of which are industrial solvents (e.g.
ethanol, acetone and chloroform), drugs (e.g. acetaminophen,
isoniazid, chlorzoxazone, trimethadione and d-benzphetamine)
and procarcinogens (e.g. benzene, N-nitrosodimethylaminen, and
styrene) [9,10,11]. The CYP2E1 gene (Chromosome 10q26.3,
Accession Number NC_000010.10) presents several genetic
polymorphisms which play an important role in interindividual
variability in drug response, drug-drug interactions and in
susceptibility to chemical-induced diseases [12,13]. Among the
known polymorphisms, the CYP2E1*1C and CYP2E1*1D allele
contain repeat sequences in the 59 flanking region which may act
as negative regulatory elements [14]. The most extensively studied
SNPs of CYP2E1 are the PstI/RsaI site in the 59 flanking region
(CYP2E1*5B; rs3813867/rs2031920) and the DraI site in intron 6
(CYP2E1*6). The CYP2E1*5 allele has been associated with
increased risk of developing antituberculosis drug-induced hepa-
titis and hyperglycemia-induced liver injury [15,16]. Recent meta-
analyses suggest that CYP2E1 PstI/RsaI and DraI polymorphisms
may affect susceptibility to many cancers such as lung cancer and
head and neck cancer [17,18]. On the other hand, CYP2E1 can
catalyze reactions to yield reactive oxygen species (ROS) resulting
from incomplete reduction of oxygen due to leakage of electrons
through the electron transport chain [19]. A cluster analysis of
transcriptional alterations showed that genes related to energy
metabolism and oxidative stress differentiated almost 90% of
schizophrenia patients from controls [20]. We therefore consid-
ered that CYP2E1 might be involved in the onset or etiology of
schizophrenia. However, apart from a case-control study of
Japanese subjects in 1997 (sample size: 41 cases and 75 controls)
with the result that no linkage of the CYP2E1 c1/c2 polymorphism
to schizophrenia has been found [21], there has been virtually no
comprehensive study of association between genetic polymor-
phisms of CYP2E1 gene and schizophrenia.
Risperidone is a benzisoxazole derivative which is widely used
as one of the first-line atypical antipsychotics in treatment and
maintenance therapy in schizophrenia and other psychotic
diseases [22]. As a second-generation antipsychotic (SGA),
risperidone has several advantages over typical antipsychotics,
including having fewer extrapyramidal side effects (EPS), lower
risk of tardive dyskinesia (TD), and improvement of both the
positive and negative symptoms of schizophrenia [23,24]. How-
ever, significant interindividual variations in response to risperi-
done with respect to both therapeutic effects and adverse side
effects have been reported [25,26]. Several genes in the drug
transporters (e.g. ATP-binding cassette (ABC) transporters) and
drug targets (e.g. dopaminergic and serotoninergic systems) have
been discovered to be correlated with risperidone efficacy, such as
ABCB1 [26], DRD2 [27], DRD3 [28], SLC6A4 [29], HTR2A [30]
and HTR2C [28]. With respect to drug metabolic enzymes, the
metabolism of risperidone to 9-hydroyrisperidone and other
metabolites is mainly mediated by CYP2D6 and CYP3A4
[31,32]. Due to their similar pharmacological characteristics, the
combined effect of the plasma concentration of risperidone plus 9-
hydroxyrisperidone, which is referred to as the ‘active moiety’, is
usually measured for drug monitoring [33]. The relationships
between CYP2D6/CYP3A4 polymorphisms and risperidone me-
tabolism have been tested but no correlation with clinical response
was found [34,35]. Since CYP2E1 metabolizes many low
molecular weight compounds including several psychotropics,
evidence suggesting that CYP2E1 polymorphisms are related to
risperidone response is insufficient.
Systematic screening of the CYP2E1 gene in the Chinese Han
population has revealed a total of 22 SNPs in the CYP2E1 gene, of
which the most frequent alleles are the wild-type allele *1 (49.5%)
followed by *7 (33.9%), and the *5 allele (16.1%) [36]. We
therefore chose to analyze CYP2E1*1C/*1D, a variable number
tandem repeat in the 5’ flanking region (59-VNTR) and 10 SNPs
(rs3813865, rs3813866, rs8192766, rs3813867, rs2031920,
rs2031921, rs3813870, rs2031922, rs2070672 and rs2070673)
with allele frequencies approximately higher than 20% in the
promoter of the CYP2E1 gene. Consequently, the purpose of this
study was to examine: 1) the association between the CYP2E1 gene
polymorphisms and schizophrenia, 2) the relationship between
CYP2E1 gene polymorphisms and the clinical efficacy of
risperidone treatment in schizophrenia patients.
Materials and Methods
Subjects
A total of 228 unrelated schizophrenic patients between 15 and
60 years of age were recruited from the Shanghai Mental Health
Center (China). The controls consisted of 384 unrelated healthy
individuals between 18 and 53 years of age. Clinical data were
collected from 130 inpatients (45 males and 85 females with a
mean age of onset of 30.3610.3 years and a mean age of
36.3611.2 years) among the 228 schizophrenics mentioned above.
All the patients were chosen according to the following criteria:
N Meeting the Diagnostic and Statistical Manual of Mental
Disorders-IV (DSM-IV) criteria [37] for schizophrenia;
N No physical complications or other psychiatric diseases such as
alcoholism or other substance abuse;
N No history suggesting resistance to antipsychotics treatment;
N Had received no medication for 4 weeks;
N Had not previously been treated with atypical antipsychotics.
All subjects recruited for this study were Han Chinese in origin.
Written informed consent was obtained from each participant
including the guardians on the behalf of the minor participants.
The study protocol was approved by the Shanghai Ethical
Committee of Human Genetic Resources.
Clinical Assessment
Before risperidone monotherapy treatment, all the patients had
been medication-free for more than 4 weeks as a ‘washout’ period.
All patients received risperidone at a daily dose ranging from 2 to
4 mg/day administered by the prescribing clinicians. The dosage
was adjusted on the basis of individual tolerance. Patients’
compliance was closely monitored and confirmed by the nursing
staff. During the medication period of 8 weeks, no other drugs
were given except biperiden for moderate EPS, sennoside for
constipation and flunitrazepam for acute insomnia. Clinical
response was assessed on the basis of clinical improvement using
the Brief Psychiatric Rating Scale (BPRS) [38]. BPRS ratings were
conducted independently by two fully qualified psychiatrists who
were blind to the genotype of each patient. Blood samples for the
determination of risperidone and 9-hydroxyrisperidone concen-
CYP2E1 and Schizophrenia/Risperidone Response
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between 8:00 and 9:00 a.m., about 12 h after the bedtime dose.
The plasma concentrations of risperidone and 9-hydroxyrisper-
idone were analyzed using high performance liquid chromatog-
raphy (HPLC) [39]. Prolactin concentrations were assayed by
radioimmunometric assay (RIA). Each patient was in a corre-
sponding steady-state condition when all the concentrations were
measured.
Genotyping
Genomic DNA was extracted from venous blood using the
QiaAmpH isolation system (Qiagen, Basel, Switzerland). The 59-
VNTR were genotyped by polymerase chain reaction (PCR) and
electrophoresed on a 1% agarose gel. The SNPs were genotyped
by direct DNA sequencing, using an ABI BigDyeH Terminator
Cycle Sequencing Kit (Applied Biosystems, CA, USA) on an ABI
PRISM 3730 DNA sequencer (Applied Biosystems). Detailed
information about primer sequences, PCR conditions and
preparation of DNA for sequencing are available on request. All
genotypes were performed by researchers who were blind to the
clinical outcome of antipsychotic treatment. All observed DNA
sequences of CYP2E1 were deposited in NCBI Genbank and
assigned with an accession number NC_000010.10.
Statistical Analysis
Statistical analyses were carried out using the program SPSS for
Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA). The case-
control study, pairwise linkage disequilibrium (LD) estimation and
haplotype reconstruction were performed using SHEsis (http://
analysis.bio-x.cn) [40]. We also used Haploview 4.2 [41] to
estimate Hardy-Weinberg equilibrium (HWE) and LD. For
accurate multiple testing correction, p values of the alleles and
genotypes were permutated 100,000 times. Gender differences of
demographic and clinical variables were tested using the Student’s
t-test. Pearson’s correlation coefficient was calculated using
GraphPad Prism 5 to examine the relationship between potential
confounding factors (age, age of onset, baseline BPRS score, levels
of active moiety, change of prolactin levels or metabolic ratio
(risperidone/9-hydroxyrisperidone)) and clinical improvements in
BPRS scores. Association tests between genotypes and percentage
reduction in BPRS scores (and other clinical parameters) were
performed using one-way analysis of variance (ANOVA). In the
analysis of genetic effects on therapeutic efficacy, univariate
analysis of variance (UNIANOVA) was carried out to adjust the
results of the association test. Variables significantly correlated
with the percentage change in BPRS scores were selected as
covariates for the control of confounding effects in UNIANOVA.
Post hoc power calculations with pre-established effect size, a error
probability and sample size were carried out using the G*Power
version 3.1.3 program [42]. All tests were two-tailed and p,0.05
was considered statistically significant.
Results
Association Study between the CYP2E1 Gene
Polymorphisms and Schizophrenia
Single marker association analyses. To investigate the
association of the polymorphisms in the CYP2E1 gene with
schizophrenia, we detected allele and genotype frequencies of 10
SNPs in the promoter of CYP2E1 and 59-VNTR in 228
schizophrenic patients and 384 healthy controls. The distribution
of the SNPs was in HWE except for rs8192766 in cases
(p=0.0094,0.05), but the deviation disappeared after Bonferroni
correction (corrected p=0.094.0.05). The data for genotype and
allele frequencies are listed in Table 1. As shown, significant
differences in allele or genotype frequencies were observed
between cases and controls at 59-VNTR (allele: p=0.0113,
OR=0.6868 95%CI=0.5131–0.9193; genotype: p=0.0063),
rs8192766 (genotype: p=0.0048) and rs2070673 (allele:
p=0.0018, OR=1.4528 95%CI=1.1487–1.8374; genotype:
p=0.0020). However, after 100000 permutations, the significant
difference in 59-VNTR (allele permutation p=0.1062; genotype
permutation p=0.0626) disappeared. Thus, rs8192766 (genotype
permutation p=0.0483) and rs2070673 (allele permutation
p=0.0199, genotype permutation p=0.0225) were identified as
being associated with susceptibility to schizophrenia.
Haplotype Association Analyses
The estimation of LD for all pairs of SNP markers showed
strong LD (r
2.0.65) for rs3813867, rs2031920, rs2031921,
rs3813870 and rs2031922 (Figure 1). Our results indicated that
the 5 SNPs were in one LD block. After excluding the haplotypes
with a frequency lower than 3% in patients and controls, only 4
haplotypes composed of the 5 SNPs were involved in the
haplotype analysis. The overall haplotype frequency revealed
significant differences between cases and controls (p=1.19E-10).
The GTCAC Haplotype which was more frequent in patients,
proved to be significantly associated with schizophrenia
(p=7.47E-12, permutation p,0.0001) (Table 2).
Association Study between the CYP2E1 Gene
Polymorphisms and Risperidone Response in
Schizophrenia Patients
Clinical Profiles. All 130 patients treated with risperidone
were available for assessment at the end of the 8-week treatment.
Of the group, 67 were drug naive and the rest had prior exposure
to conventional neuroleptics. 15 patients withdrew from the study
because of concurrent somatic illness (n=3), lack of efficacy (n=6)
or noncompliance (n=6). Clinical profiles of the patients are
displayed in Table 3. The patients were divided into two groups
based on gender. Other than for baseline prolactin levels, there
were no significant differences between sex groups in age, age of
onset, steady-state plasma concentrations of risperidone and 9-
hydroxyrisperidone, or in baseline BPRS scores on admission.
This demonstrated that our sample data had no gender bias for
primary clinical parameters. At the end of the 8-week treatment,
72 patients showed a reduction in BPRS scores .40% and were
classified as responders and the other 58 patients were classified as
non-responders. No significant differences in demographic char-
acteristics or plasma levels of risperidone and 9-hydroxyrisper-
idone were found between the two groups (p.0.05) (data not
shown).
Using Pearson’s correlation analysis, we found that the baseline
BPRS scores exerted a significant influence (r=0.567, n=130,
p,0.001) on treatment efficacy as measured by the percentage
reduction of BPRS scores, while no significant correlations
between independent variables, such as age, age of onset, plasma
active moiety, change of prolactin levels or metabolic ratio and the
improvement of BPRS scores were found (Figure S1). Conse-
quently, the baseline BPRS score was selected as a covariate to
adjust for confounding effects in the analysis of association
between CYP2E1 genotypes and symptom improvement.
Effects of individual polymorphisms on clinical symptom
improvement. All 11 polymorphisms were successfully geno-
typed in the 130 schizophrenic patients. For the 10 SNPs, no
significant deviation from HWE was found in any of the subjects
except for rs8192766 (p=0.01,0.05). Table 4 shows the
CYP2E1 and Schizophrenia/Risperidone Response
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among groups according to different genotypes. No significant
association between percentage change of BPRS score and
genotypes was observed before or after adjustment for the
covariate effects (p.0.05). Moreover, there were no significant
differences in allele or genotype frequencies in any of the 11
polymorphisms between the responder and non-responder groups
(data not shown). These results suggest that CYP2E1 polymor-
phisms exhibit no significant effect on risperidone efficacy.
Additionally, there were several significant discrepancies between
genotypic subgroups of CYP2E1 polymorphisms in clinical
parameters (p,0.05), such as active moiety which had positive
association with rs3813866, rs3813867, rs2031920, rs2031921,
rs2031922 and change of prolactin levels which had positive
association with rs8192766 (Table S1).
LD between SNPs and haplotype analysis. Pairwise LD
between the 10 SNPs is shown in Table 5. Based on LD
determinations, rs3813867, rs2031920, rs2031921, rs3813870 and
rs2031922 were in moderate LD. These 5 SNPs with strong LD
were included in the haplotype analysis. The 4 haplotypes with a
frequency higher than 3% accounted for the majority of the
haplotype diversity. The frequencies of the common haplotypes
were compared between responders and non-responders. As
shown in Table 6, there were no significant differences in
haplotype distributions between the two groups (global
x
2=0.574, p=0.902).
Discussion
Our two-part study investigated the contribution of polymor-
phisms in the CYP2E1 gene to both schizophrenia susceptibility
Figure 1. LD plot for CYP2E1. The LD plots were generated by Haploview 4.2. r
2 between marker pairs is indicated by the shaded matrices. This
figure shows that strong LD was observed between rs3813867, rs2031920, rs2031921, rs3813870 and rs2031922.
doi:10.1371/journal.pone.0034809.g001
Table 2. Estimated CYP2E1 haplotype frequencies and p values among cases and controls.
Haplotype (rs3813867-rs2031920-
rs2031921-rs3813870-rs2031922) Case Frequency (%) Control Frequency (%) p value
Permutation p
value OR [95% CI]
C T C A C 15.5 19.3 0.0662 0.5671 0.742 [0.540–1.021]
G C T A T 56.6 58.7 0.2116 0.9955 0.856 [0.671–1.092]
G C T G T 18.0 18.1 0.7795 1.0000 0.957 [0.701–1.305]
G T C A C 9.7 0.9 7.47E-12 ,0.0001 11.348 [4.811–26.767]
Global 1.19E-10 ,0.0001
Only haplotypes with a frequency higher than 3% are listed.
OR: Odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0034809.t002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e34809Table 3. Clinical characteristics and baseline demographics of schizophrenia patients treated with risperidone.
Features Total (n=130) Male (n=45) Female (n=85) p value
Age (years) 36.3611.2 35.9612.8 36.4610.4 0.798
Age of onset (years) 30.3610.3 28.4610.6 31.3610.1 0.132
Plasma risperidone levels (ng/ml) 7.666.3 7.066.4 7.966.3 0.469
Plasma 9-hydrorisperidone levels (ng/ml) 23.4616.2 23.9621.1 23.1613.2 0.789
Baseline Prolactin (mIU/L) 775.26733.8 508.06340.2 907.26835.5 0.004*
Baseline BPRS score 42.4612.4 42.2612.6 42.5612.3 0.879
Data are shown as mean6SD. BPRS: Brief Psychiatric Rating Scale. *Significant difference (p,0.05) between males and females.
doi:10.1371/journal.pone.0034809.t003
Table 4. Comparison of reduction in BPRS score between genotype subgroups after the 8-week treatment.
BPRS
Marker Genotype Frequency (%) p value for HWE Baseline Percentage reduction p value Adjusted p value
6/6 73(56.1) 41.5611.7 40.4617.6
59-VNTR 6/8 53(40.8) 0.21 44.0613.2 41.9616.3 0.167 0.234
8/8 4(3.1) 37.8615.0 25.0622.0
GG 86(66.2) 42.6613.1 41.6618.2
rs3813865 GC 42(32.3) 0.33 41.9611.0 39.3614.7 0.322 0.156
CC 2(1.5) 45.0615.6 24.4632.0
TT 74(56.9) 43.5612.4 41.1617.6
rs3813866 TA 51(39.2) 0.40 40.2610.3 39.0617.2 0.496 0.540
AA 5(3.9) 48.8625.9 48.0614.3
TT 37(28.5) 42.9612.1 41.9617.8
rs8192766 TG 78(60.0) 0.01* 41.8611.8 39.8617.4 0.819 0.833
GG 15(11.5) 44.3616.0 41.3616.3
GG 90(69.2) 42.6611.7 40.5617.0
rs3813867 GC 35(26.9) 0.64 40.9611.7 39.6618.5 0.599 0.799
CC 5(3.9) 48.8625.9 48.0614.3
CC 66(50.8) 43.5612.4 40.9618.0
rs2031920 CT 57(43.8) 0.50 41.0610.5 39.7616.9 0.771 0.762
TT 7(5.4) 43.1623.4 44.6614.5
TT 66(50.8) 43.5612.4 40.9618.0
rs2031921 TC 57(43.8) 0.50 41.0610.5 39.7616.9 0.771 0.762
CC 7(5.4) 43.1623.4 44.6614.5
AA 87(66.9) 41.9612.9 40.9618.0
rs3813870 AG 41(31.6) 0.43 43.2611.3 40.7615.1 0.416 0.174
GG 2(1.5) 45.0615.6 24.4632.0
TT 66(50.8) 43.5612.4 40.9618.0
rs2031922 TC 57(43.8) 0.50 41.0610.5 39.7616.9 0.771 0.762
CC 7(5.4) 43.1623.4 44.6614.5
AA 93(71.5) 41.9612.9 40.7618.0
rs2070672 AG 36(27.7) 0.36 43.3610.9 41.3614.5 – –
GG 1(0.8) – –
AA 24(18.5) 40.7614.1 39.1618.2
rs2070673 AT 77(59.2) 0.07 42.7611.6 40.5616.8 0.833 0.928
TT 29(22.3) 43.0613.1 42.0618.2
VNTR : Variable number tandem repeat; BPRS: Brief Psychiatric Rating Scale; HWE: Hardy-Weinberg equilibrium.
*Significant difference (p,0.05) showed deviation from HWE.
doi:10.1371/journal.pone.0034809.t004
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population-based association analysis. We found statistically
significant association for SNP rs8192766 and rs2070673 of the
CYP2E1 gene with schizophrenia. We also found that the
haplotype consisting of rs3813867, rs2031920, rs2031921,
rs3813870 and rs2031922 (GTCAC) was significantly associated
with schizophrenia as shown by its overrepresentation in cases
(OR=11.348 95%CI=4.811–26.767, p=7.47E-12, permutation
p,0.0001). Significantly, rs8192766 deviated from HWE, indi-
cating possible inbreeding or population stratification. However,
deviation in samples of affected individuals can also provide
evidence for association [43]. While haplotype analysis revealed a
significant association with schizophrenia, none of the single SNPs
in this haplotype showed positive association. This may be due to
the fact that haplotype analysis has a higher power than individual
genetic markers in association analysis, given that haplotype
analysis underlines the correlation between the individual markers.
Our study has, for the first time, provided evidence for an
association pattern of CYP2E1 polymorphisms with schizophrenia
in a Chinese Han population. However, no association of CYP2E1
gene polymorphisms or related haplotypes with risperidone
efficacy was found in the second part of the study. Post hoc
power analysis revealed that the statistical power of the total
sample size (228 cases VS 384 controls) in the case-control study
was 0.95 as regards the association analysis with effect size d=0.3,
a=0.05. For the pharmacogenomics study, the statistical power of
the sample size (n=130) in detecting significant association
(p,0.05) was 0.87 with a medium effect size (d=0.3). These
results indicate that the sample size in our study was sufficient to
achieve a considerably low risk of a type II error.
CYP2E1, which makes up only 1% of all the hepatic P450
isoforms, plays an important role in the metabolism of low
molecular weight compounds and drugs. There is evidence to
suggest that interindividual variability in the expression and
functional activity of CYP2E1 may be considerable. Genetic
polymorphisms in CYP2E1 have been linked to altered suscepti-
bility to liver injury, head and neck cancer and other carcinomas
in some epidemiological studies [16,18]. There are many CYP2E1
variant alleles but the functional significance of these variants is
still unknown. None of the coding region variants consistently
affects enzyme function, partially due to the fact that there are
extremely rare polymorphisms in the coding regions of the
CYP2E1 gene. Therefore, any association study with human
disease risk would require a high number of samples to generate
enough statistical power. One novel nonsense mutation, which
could result in the change of Arg to stop codon and a total loss of
enzyme activity, has been detected for the first time in the Chinese
population [36]. However, the mutation frequency presented only
0.5% and the effect on expression of the CYP2E1 gene needs to be
further investigated. Many studies have indicated that several
upstream 59 flanking mutations affect gene expression and
response to inducers such as ethanol or obesity [13,14]. Hence,
our primary focus was on polymorphism in the 59 flanking region
that appear to influence gene expression.
Table 5. Pairwise polymorphisms LD analysis.
rs3813865 rs3813866 rs8192766 rs3813867 rs2031920 rs2031921 rs3813870 rs2031922 rs2070672 rs2070673
rs3813865 0.997 1.000 0.999 0.999 0.999 0.861 0.999 0.899 1.000
rs3813866 0.066 1.000 1.000 0.952 0.952 0.999 0.952 0.998 0.909
rs8192766 0.302 0.431 1.000 0.783 0.783 0.887 0.783 0.861 0.941
rs3813867 0.045 0.683 0.295 0.966 0.966 0.998 0.966 0.995 0.872
rs2031920 0.081 0.740 0.324 0.520 1.000 0.999 1.000 0.999 0.889 D’
value
rs2031921 0.081 0.740 0.324 0.520 1.000 0.999 1.000 0.999 0.889
rs3813870 0.722 0.064 0.232 0.044 0.078 0.078 0.999 0.967 1.000
rs2031922 0.081 0.740 0.324 0.520 1.000 1.000 0.078 0.999 0.889
rs2070672 0.644 0.052 0.179 0.035 0.064 0.064 0.765 0.064 1.000
rs2070673 0.232 0.273 0.679 0.172 0.321 0.321 0.226 0.321 0.185
r
2 value
doi:10.1371/journal.pone.0034809.t005
Table 6. Frequencies of estimated haplotypes and test statistics between responders and non-responders.
Haplotype (rs3813867-rs2031920-rs2031921-rs3813870-
rs2031922) Responders Non-responders x
2 p value OR [95%CI]
C T C A C 0.181 0.154 0.292 0.589 1.199 [0.620–2.320]
G C T A T 0.542 0.559 0.135 0.713 0.912 [0.557–1.493]
G C T G T 0.180 0.164 0.101 0.751 1.111 [0.580–2.129]
G T C A C 0.097 0.114 0.209 0.647 0.831 [0.375–1.841]
Global 0.574 0.902
Only haplotypes with a frequency higher than 3% are listed.
OR: Odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0034809.t006
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e34809CYP2E1, a potent producer of ROS, primarily expresses in the
liver but also exists in extrahepatic tissues, including the brain
[19,44]. Induction of this enzyme in astrocytes causes oxidative
stress, leading to increased production of metabolites of lipid
peroxidation and decreased concentrations of glutathione [45],
both of which are also seen in the brain in schizophrenia,
Parkinson’s disease and Alzheimer’s disease [46]. Accordingly, we
suspected that subjects with certain polymorphisms and haplotypes
of CYP2E1 might have an increased ability to activate endogenous
or exogenous toxins, leading to increased oxidative stress in the
brain and, therefore, an increased relative risk of schizophrenia.
On the other hand, low CYP2E1 activity might protect individuals
from schizophrenia because of the lower production of metabolites
of ROS. There is also evidence to suggest that hyperactivity of
dopaminergic neurons generates excess ROS in the acute stage of
schizophrenia, which leads to subsequent neuronal damage and
chronic disability [47]. Later, it was reported that aminochrome-
dependent neurodegeneration of dopaminergic neurons in the
mesolimbic system may contribute to the development of
schizophrenia. Aminochrome, an oxidation metabolite of dopa-
mine, is metabolized by NADPH-cytochrome P450 reductase to
the highly neurotoxic o-semiquinone releasing large amounts of
ROS. On the other hand, glutathione transferase M1b (GST-
M1b) inhibits the formation of ROS during one-electron reduction
of aminochrome catalyzed by NADPH-cytochrome P450 reduc-
tase [48]. Any defect in the mechanisms responsible for
detoxification could lead to an excess of o-semiquinone and
ROS in the dopaminergic, noradrenergic, or adrenergic nerve
system, and finally to neurological disorder. Recent results also
suggest a genetic effect of prolactin polymorphisms in prolactin
levels indicating that independently of antipsychotic therapy
subjects could have altered prolactin levels due to their genetic
background [49]. In addition, prolactin can regulate oligodendro-
cyte precursor cells proliferation and promote intrinsic myelin
repair, and may have potential for the treatment of neurological
disorders [50]. Previous case-control studies aiming at the same
cohort also have found some other candidate genes related to
schizophrenia [51,52]. Accordingly, it is possible that the
combined effect of CYP2E1 and other genes in related pathways
might contribute to this complex disease. It is noteworthy that
these schizophrenia susceptibility genes can be grouped into
distinct families which reflect the processes disrupted in the
schizophrenic brain and certain gene clusters can be linked
together to form a defined signaling cascade involved in the N-
methyl-D-aspartate (NMDA) receptor-dependent long-term po-
tentiation and synaptic plasticity, that may be interconnected with
oligodendrocyte and oxidative stress-related pathways [53].
Therefore, potential gene-gene interactions with respect to the
schizophrenia phenotype measured in this cohort need further
investigation. In addition, further accumulation of data on the role
of the CYP2E1 polymorphisms in the pathogenesis of schizophre-
nia and cellular or protein expression experiments should be
conducted.
With regards to the pharmacogenomic association study of
CYP2E1, 11 polymorphisms tested in the first case-control study
were also investigated for their possible association with risperidone
response in the 130 unrelated schizophrenic patients. Assessing the
relationship between the plasma concentration of antipsychotics and
therapeutic efficacy could be considerable. Therefore, we first
investigated the correlation between plasma active moiety concen-
tration and clinical effect in all 130 schizophrenia patients after 8
weeks of risperidone treatment. Although it has been reported that
concentration of active moiety was associated with improvement of
Positive and Negative Syndrome Scale (PANSS) [54], we found no
significant relationship between plasma active moiety and percent-
age improvement of BPRS scores which accords with a study by
Spina et al [55]. This further indicates that active moiety
concentration may not be a suitable tool for predicting the treatment
effectinschizophreniapatients.Analysisoftheclinicalcharacteristics
of the patients in our study shows that the baseline of prolactin levels
in females was significantly higher than in males, which is consistent
with normal gender differences (Table 3). In addition, several other
potential confounding factors, such as age, age of onset, baseline
BPRS scores, change of prolactin levels and metabolic ratio were
examined in the context of BPRS score improvements in order to
eliminate non-genetic effects in the statistical analysis. Finally,
significant correlation was only observed in baseline BPRS scores
(Figure S1). Additionally, the significant differences between
genotypic subgroups of CYP2E1 polymorphisms in several clinical
parameters (Table S1) are not relevant to the clinical efficacy of
risperidone. For instance, the change of prolactin levels has positive
association with rs8192766 but negative with the risperidone
response, which could be interpreted by the previous finding that
antipsychotic drugs modulate prolactin levels but prolactin is not a
steady indicator of treatment outcome [56]. We therefore selected
baseline BPRS scores as the covariant in adjusting ANOVA.
Nevertheless, no association between any genetic markers and
general symptom improvement was observed. Furthermore, we
found no significant difference of allele, genotype or haplotype
frequencies between responder and non-responder groups.
The current study attempted to confirm genetic contributors to
the symptom variability in risperidone efficacy. Contrary to our
expectation, the results indicated that the effect of variations in the
CYP2E1 gene on therapeutic efficacy of risperidone appeared
weak or non-existent. However, further replication studies are
warranted to identify whether or not CYP2E1 genotypes are
clinically related in the antipsychotic treatment, as the second part
of the study had a relatively small sample number.
In conclusion, the case-control study revealed that CYP2E1
polymorphisms were associated with susceptibility to schizophre-
nia in the Chinese Han population. On the other hand, the results
in the pharmacogenomic study indicated that there is no positive
association between CYP2E1 polymorphisms and risperidone
therapeutic effect. Since CYP2E1 polymorphism frequencies show
variability across different races and ethnicities, as do most other
xenobiotic-metabolizing enzymes. The frequencies and alleles
detected in Han population are similar to those in the Japanese
and other Asian populations. However, the comparison with
Europeans, Americans, and some other Caucasians showed
significant differences. For instance, CYP2E1*7 showed a high
frequency of 33.9% in Chinese Han population compared to 3.7%
among German [36]. Therefore, replication of these findings in
large independent samples within populations with different
genetic background is essential to help confirm the results.
However, data from our study may provide a basis for future
investigations on the role which CYP2E1 plays in the etiology of
schizophrenia and risperidone treatment outcome.
Supporting Information
Figure S1 Correlations between potential confounding
factors and the improvement of BPRS scores.
(TIF)
Table S1 Comparison of clinical parameters between
genotypic subgroups of CYP2E1 polymorphisms after
the 8-week treatment.
(DOC)
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